SEOM clinical guideline for the management of cutaneous melanoma (2020)
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Manzano, J. L. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Marquez-Rodas, I. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Mujika, K. (Department of Medical Oncology. UGC de Oncología de Gipuzkoa. OSI Donostialdea-Onkologikoa)
Muñoz-Couselo, E. (Vall d'Hebron Institut d'Oncologia)
Pérez-Ruiz, E. (Instituto de Investigación Biomédica de Málaga)
de la Cruz Merino, Luis (Universidad de Sevilla)
Espinosa, E. (Hospital Universitario La Paz (Madrid))
Gonzalez-Cao, M. (Oncology Department (IOR). Hospital Dexeus)
Berrocal, A. (Department of Medical Oncology. Consorcio Hospital General Universitario de Valencia)

Date:	2021
Abstract:	Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Melanoma ; Adjuvant treatment metastatic treatment ; Staging
Published in:	Clinical & translational oncology, Vol. 23 Núm. 5 (may 2021) , p. 948-960, ISSN 1699-3055

DOI: 10.1007/s12094-020-02539-9
PMID: 33651321

13 p, 822.1 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles